Hematopoiesis is the cumulative result of intricately regulated signaling pathways that are mediated by cytokines and their receptors. Proper culmination of these diverse pathways forms the basis for an orderly generation of different cell types. Recent studies conducted over the past 10-15 years have revealed that hematopoietic cytokine receptor signaling is largely mediated by a family of tyrosine kinases termed Janus kinases (JAKs) and their downstream transcription factors termed STATs (signal transducers and activators of transcription). Aberration in these pathways, such as that caused by the recently identified JAK2V617F mutation, is an underlying cause for diseases such as leukemias and other myeloproliferative disorders. This recent discovery, when coupled with the fact that STATs are activated by oncoproteins such as BCR-ABL, underscores the importance of the JAK-STAT pathway in both normal cellular development and disease states.
Introduction
From embryogenesis to adulthood, hematopoiesis occurs via a series of proliferative and differentiative pathways, where pluripotent, multipotent and lineage-committed cells and intermediates develop into various types of mature and functional blood cells. At each stage of this process, a precursor cell must divide and expand before further differentiating along a given pathway to maintain steady-state levels of each cell type. Hematopoietic stem cells lay the groundwork for this hierarchy and are maintained in constant numbers in the bone marrow, where they are found in a quiescent state (reviewed in Ema and Nakauchi, 2003; Durand and Dzierzak, 2005) . According to simplified models, after a series of divisions, pluripotent hematopoietic stem cells will yield committed progenitor cells. Although these cells retain stem cell-like properties, their fate is more restricted toward a particular lineage as it has been possible to isolate common lymphoid and common myeloid progenitor cells that display preferences to the lymphoid and myeloid lineages, respectively. Common lymphoids will ultimately develop into T and B lymphocytes, whereas common myeloid progenitors will eventually give rise to erythrocytes, megakaryocytes (Meg-E fate) or monocytes/macrophages and granulocytes (GM fate) (reviewed in Rosmarin et al., 2005) . Over the past few decades, dedicated work from many groups has established that hematopoietic cell growth and differentiation are mediated by a group of soluble factors known as cytokines (Hunter, 1993; Stahl and Yancopoulos, 1993; Kishimoto et al., 1994; Taniguchi, 1995) .
Cytokines and their receptors
Cytokines are a group of polypeptide growth factors that bind to their cognate receptors and mediate intracellular signaling events that result in the modulation of gene expression. At the basic structural level, most cytokine receptors consist of a multisubunit complex: a unique and specific ligand-binding subunit and a signal-transducing subunit, which may be structurally similar to other members of the cytokine receptor superfamily (Hunter, 1993; Stahl and Yancopoulos, 1993; Kishimoto et al., 1994; Taniguchi, 1995) . The average extracellular domain comprises approximately 210 amino acids and contains one or more conserved cysteine (C) residues. In addition, a second conserved sequence of tryptophan-serine-X-tryptophan-serine (W-S-X-W-S), where X refers to any non-conserved amino-acid residue, is present in the C terminus (Miyajima et al., 1992) . Structurally, this region is also composed of two fibronectin type III modules. A hinge region connects these two modules, each of which comprises approximately 100 amino acids. This region, which also houses the W-S-X-W-S motif, is predicted to function as a ligand-interaction domain. Site-directed mutational analysis within the hinge region, particularly the W-S-X-W-S motif, abolishes or greatly reduces the ligand-binding capacity of the receptors (Barry et al., 1997) . The cytoplasmic domains of cytokine receptors share a limited level of similarity in their membrane proximal regions, particularly in regions termed the box 1 or the proline-rich motif and the box 2 motif (box 1/proline-rich motifs are characterized by the sequence Al-Ar-Pro-XAl-Pro-X-Pro or Ar-X-X-X-Al-Pro-X-Pro, where Al ¼ aliphatic; Ar ¼ aromatic; and X ¼ any amino acid). These portions of the receptor are critical for proper function of the receptor and mediating mitogenic signals. In contrast, the membrane distal region, which also contains box 1 and two motifs, is required for differentiation. Functions of regions within the cytoplasmic domains that do not contain box 1 or box 2 motifs vary from receptor to receptor (reviewed in Ihle et al., 1995) .
Although hematopoietic cytokine receptors are grouped together as such due to the presence of shared motifs within their extracellular domains, they can be further subdivided into families based on the number of subunits and/or the presence of one or more shared subunits (Hunter, 1993; Stahl and Yancopoulos, 1993; Kishimoto et al., 1994; Ihle et al., 1995; Taniguchi, 1995) . The main cytokine receptor subtypes are (i) those that signal through gp130 or a gp130-related subunit, (ii) those that signal through a common g-chain (g c ) and a-and/or b-ligand-binding subunits, (iii) those that signal through a single chain, (iv) those that signal through two or more subunits and (v) those that signal through the gp140b-subunit and a ligand-binding asubunit (Figure 1) . A detailed description of the features of each of these families is beyond the scope of this review, and hence we only provide a few salient features of these protein families.
The gp130 family: cytokines that signal through gp130 or a gp130-related subunit
Receptors for interleukin-6 (IL-6), IL-11, IL-12, cardiotropin-1, ciliary neurotrophic factor, oncostatin M and leukemia inhibitory factor, all signal through a common b-chain termed gp130. Apart from this common gp130 signal-transducing subunit, each of the above-mentioned receptors possesses a unique and specific ligand-binding a-subunit.
The interleukin-2 receptor family: cytokines that signal through a common c-chain and a-and/or b-ligand-binding subunits The IL-2 receptor (IL-2R) consists of three subunits, a, b and g, of which the g-chain (IL-2Rg-chain) is shared by receptors for IL-4, IL-7, IL-9 and IL-15. Each of these receptors, similar to the IL-2R, consists of three subunits, termed a, b and g. Of these, the a-subunit acts as the ligand-binding subunit, whereas the b-and g-subunits function as signal-transducing subunits. The IL-2Rg-chain associates with Janus kinase-3 (JAK3) and mutations in either IL-2Rg-chain or JAK3 result in a non-functional receptor, which abrogates signaling via IL-2, IL-7, IL-9 and IL-15 (Russell et al., 1994 (Russell et al., , 1995 .
The growth hormone family: cytokines that signal through a single chain This family includes receptors for growth hormone, prolactin (PRL), erythropoietin (EPO), granulocytecolony-stimulating factor and thrombopoietin. These receptors consist of a single subunit that forms homodimers upon ligand binding. Although structurally similar, they do not crossreact with ligands of other receptors and transduce signals that are specific for a given cytokine.
The interferon family: cytokines that signal through two or more subunits This family comprises the interferon (IFN)-a receptor (IFNAR), the IFN-g receptor (IFNGR) and the IL-10R. The IFNGR also has two chains, IFNGR1 and IFNGR2. The IL-10R comprises two chains, IL-10R1 and IL-10R2. In the case of these receptors, both subunits function as signal-transducing components of the receptor and bind to downstream signaling proteins such as JAKs and signal transducers and activators of transcriptions (STATs).
The gp140 family: cytokines that signal through the gp140b-subunit and a ligand-binding a-subunit This family includes the receptors for cytokines, IL-3, IL-5 and granulocyte macrophage-colony-stimulating factor. The IL-3 and GM-CSF genes located on the 5q region of chromosome 5 have been associated with hematopoietic malignancies, underlining the importance of these cytokines in hematopoietic signaling (Blalock et al., 1999) . The receptors for these cytokines have unique ligand-binding-a chains and share the common b (gp140) signal-transducing subunit (Gearing et al., 1989; Hayashida et al., 1990; Itoh et al., 1990; Murata et al., 1992) .
Signal-transduction pathways activated by cytokines
Molecular cloning of cytokine receptors and subsequent structure-function studies has revealed that unlike growth factor receptors, cytokine receptors are devoid of catalytic activity. Nevertheless, interaction of a cytokine with its receptor rapidly induces tyrosine phosphorylation of the receptor and a variety of cellular proteins, suggesting that these receptors transmit their signals through cellular tyrosine kinases (Kishimoto et al., 1994) . During the past 10-15 years, a large amount of experimental data have accumulated to indicate that most cytokines transmit their signals via a distinct family of tyrosine kinases termed Janus kinases or JAKs (Table 1; Ihle et al., 1997; Darnell et al., 1994) .
Janus kinases
There are four members of the JAK family, JAK1, JAK2, JAK3 and TYK2. Of these, TYK2 was the first to be discovered (Firmbach-Kraft et al., 1990) and bore some resemblance to known tyrosine kinases. Shortly thereafter, cDNAs encoding JAK1 (Wilks et al., 1991) , JAK2 (Harpur et al., 1992) and JAK3 Rane and Reddy, 1994; Takahashi and Shirasawa, 1994) were isolated using various cloning strategies.
The unique structure of the JAKs clearly distinguishes them from other members of the protein tyrosine kinase family (Figure 2 ). The most intriguing feature of these proteins is the presence of two Jak homology (JH) domains, JH1 and JH2, which have extensive homology to tyrosine kinase domains. Although the JH1 domain is a functional tyrosine kinase domain, the JH2 domain, despite harboring most of the conserved amino acids that are a characteristic of functional kinases, lacks any observable tyrosine kinase activity due to the absence of residues that are required for catalytic activity and nucleotide binding. However, it is now clear that this kinase-like domain plays a significant regulatory role in the activity of both JAK family proteins and cytokineinduced signaling. For example, deletion of the JH2 domain in both Jak2 and Jak3 has been shown to result in increased phosphorylation of these mutants as well as STAT-5 (Saharinen et al., 2000; Saharinen and Silvennoinen, 2002) , suggesting that this domain is required for inhibiting the basal activity of these proteins. Furthermore, expression of these JH2-deficient proteins in factor-dependent cell lines results in cytokineindependent signaling. A more detailed analysis of the Jak2 JH2 region using recombinant proteins indicates that this domain suppresses basal JAK2 activity by lowering the V max of the kinase without affecting its K m for a substrate peptide (Saharinen et al., 2003) . Additional studies have revealed the presence of three inhibitory regions (1-3) that regulate the autoinhibitory activity of this kinase as well as a novel phosphorylation site at tyrosine 570 that regulates responses to cytokines (Saharinen et al., 2003; Feener et al., 2004) . Taken together, these studies indicate that the JH2 domain is critical in the ability of JAKs to regulate themselves as well as mediate cytokine-induced responses.
The importance of the JH2 domain in the regulation of JAK activity has been recently underscored in patients suffering from myeloproliferative disorders, in particular, those whose cells express the mutant JAK2 V617F protein (Baxter et al., 2005; James et mutation is believed to disrupt the inhibitory role that the JH2 domain has on JH1, whereby the activation loop of JH1 adopts a conformation such that it can be phosphorylated by an adjacent JAK2 V617F molecule. As a result, cells that express this protein display increased levels of phosphorylated, activated JAK2. In addition, a number of severe combined immunodeficiency patients have mutations in the JH2 domain of JAK3 (reviewed in O' Shea et al., 2002) , further signifying the role that this domain plays in the regulation of JAK proteins.
At the time the JAKs were cloned and initially characterized, it was believed that the sequences of the JH3-JH7 domains bore little resemblance to any characterized protein motif. However, it is now widely accepted that the N-terminal-half of JAKs contains two motifs, an Src homology-2 (SH2) domain and a band Four-point-one, Ezrin, Radixin, Moesin (FERM) domain. The SH2 domain encompasses what is defined as the JH3 and JH4 domains. However, in spite of the homology to SH2 sequences, this region does not appear to bind to phosphotyrosine residues (Higgins et al., 1996; Kampa and Burnside, 2000; reviewed in Haan et al., 2006) . The JH6-JH7 domains comprise the FERM domain, which regulates catalytic activity and mediates association with receptors and other proteins. Residues located in the JH7 domain mediate binding to the box 1/ proline-rich region of cytokine receptors (Pellegrini and Dusanter-Fourt, 1997; Richter et al., 1998; Haan et al., 2002) . In addition, this interaction between JAKs and cytokine receptors ultimately regulates receptor localization and turnover (Gauzzi et al., 1997; Ragimbeau et al., 2003) . Specifically, surface expression of EPO receptor can be regulated by the FERM domain of JAK2 , and both JAK2 and TYK2 have been shown to inhibit the proteasomal degradation of the thrombopoietin receptor by facilitating its expression at the cell surface. Recently, Funakoshi-Tago et al. (2006) have identified a regulatory tyrosine residue in JAK2, Y119, which when phosphorylated following receptor dimerization, causes the protein to dissociate from the receptor and undergo degradation. Thus, JAK FERM domains can both positively and negatively regulate the protein's ability to mediate responses to cytokines.
Receptors are primary substrates of Janus kinases activation
The importance of JAKs in mediating signals from a variety of cytokines/growth factors underscores their role in signal transduction in general. However, the complexity associated with processing signals from such diverse sources suggests a complicated mechanism of action for JAKs. Although the precise mechanism by which ligand binding results in the activation of JAKs is not known, inferences from the results of various studies have allowed the proposition of models to explain the mechanism of activation of JAKs. JAKs, when ectopically expressed in the baculovirus system, are enzymatically active and are phosphorylated on tyrosine residues. Their overexpression in mammalian cells also leads to constitutive activation, most probably due to dimerization (Colamonici et al., 1994a, b; Yamamoto et al., 1994; Duhe and Farrar, 1995; Quelle et al., 1995; Wang et al., 1995; Eilers et al., 1996) . On the other hand, a JAK in complex with a native un-liganded receptor is in a catalytically inactive latent state. Receptor dimerization/oligomerization due to ligand binding results in the juxtapositioning of the JAKs, which are in the vicinity through either homo-or heterodimeric interactions. The recruitment of JAKs appears to result in their phosphorylation, either via autophosphorylation and/or cross phosphorylation by other JAKs or via other families of tyrosine kinases. This activation is presumed to result in increased JAK activity. Activated JAKs then phosphorylate receptors on target tyrosine sites. The phosphotyrosine sites on the receptors can then serve as docking sites that allow the binding of other SH2-domain containing signaling molecules such as STATs, Src-kinases, protein phosphatases and other adaptor signaling proteins such as Shc, Grb2 and phosphatidylinositol 3-kinase (PI3K) (Figure 3 ; reviewed in Wojchowski et al., 1999).
The above model is supported by several studies where investigators have demonstrated the ability of cytokines such as EPO to rapidly induce receptor oligomerization leading to JAK2 activation (Watowich et al., 1994) . Furthermore, studies using chimeric receptors with various combinations of extracellular ligand binding and cytoplasmic domains also favor this model (Jubinsky et al., 1993; Eder et al., 1994; Watowich et al., 1994; Ihle et al., 1995) , which readily applies to both single-chain receptors such as those for EPO, PRL, growth hormone and granulocyte-colonystimulating factor as well as multichain receptors such as those for IL-3, IL-5 and GM-CSF. Cytokine binding results in the association of the JAKs with one of the subunits. The receptor-associated JAK either can then process the signal or, subsequent to receptor oligomerization, can recruit other JAKs in the vicinity. Homo-or JH7  JH6  JH5  JH4  JH2  1  H  J  JH3   PSEUDO TK  TK  FERM  SH2 V617F (Jak2) Figure 2 Structure of Janus kinases (JAKs). JAKs harbor four functional domains, the FERM domain, the SH2 domain, the pseudotyrosine kinase (TK) domain and a catalytically active TK domain. Although the JH2 region is not a functional tyrosine kinase, this domain negatively regulates the activity of JAK proteins. Also shown are the FERM and SH2 domains, which serve as receptor association and phosphotyrosine-binding domains, respectively, and the Jak2 V617F mutation that is found in myeloproliferative disorders. heterodimerization of the JAKs followed by their activation upon phosphorylation finally results in the propagation of the initial signal.
The JAK2 V617F mutation clinically signifies the importance of the interaction between cytokine receptors and JAKs. This gain-of-function mutant, unlike the chimeric JAK2 fusion proteins that result from chromosomal translocations, does not contain dimerization sequences and thus, is monomeric and unable to phosphorylate another molecule, in trans, in the absence of cytokine (reviewed in Valentino and Pierre, 2006) . However, in cells that express sufficient levels of a homodimeric type I cytokine receptor, such as Epo receptor or granulocyte-colony-stimulating factor receptor, JAK2
V617F can promote proliferation in the absence of cytokine. In this situation, the receptor is predicted to act as a scaffold, whereby each chain of the homodimer binds to JAK2 V617F , thereby allowing the kinase to undergo trans-phosphorylation (Lu et al., 2005) .
Signal transducers and activators of transcription
A little more than a decade ago, researchers deciphered a signaling pathway that initiates within the cytoplasm but quickly translocates to the nucleus to activate transcription of target genes. This signaling pathway features a group of transcription factors termed signal transducers and activators of transcription, or STATs. These transcription factors were originally described by Darnell et al. (1994 Darnell et al. ( , 1997 as ligand-induced transcription factors in IFN-treated cells. Subsequent studies by a number of groups showed that STATs play a critical role in signal-transduction pathways triggered by several cytokines and neurokines (Table 1 ; reviewed in O'shea et al., 2002) . To date, seven mammalian STAT-encoding genes have been identified. Alternative splicing or posttranslational proteolytic cleavage reactions appear to generate additional forms of STAT-1 and -3. Thus, two isoforms of STAT-1 have been described, which have been termed as STAT-1a or p91 and STAT-1b or p84. STAT-3 also exists in two forms, termed STAT-3a and -3b, with different transcriptional activation functions (Schaefer et al., 1995) . STAT-4 also exists in two forms, termed STAT-4a and -4b. Two STAT-5 isoforms, termed STAT-5a and -5b, are encoded by two separate genes that are linked in tandem Lin et al., 1996) . The two proteins exhibit extensive sequence homology and differ from each other mainly in the N-and C-terminal domains, with the transactivation domain being the most divergent.
Similar to most transcription factors, STATs exhibit a modular structure with six well-defined domains, including an N-terminal-conserved domain, a coiledcoil domain, a DNA binding domain, a linker region, an SH2 domain and a C-terminal transactivation domain (Figure 4 ). The N-terminal region of STATs is well Kisseleva et al., 2002) . The DNA-binding domain is also highly conserved among the STATs, and all STAT homodimers with the exception of STAT-2 differentially bind more than 10 related g-activated sequence elements that are characterized by the consensus sequence, TTNCNNNAA (Horvath et al., 1995; Xu et al., 1996) Schindler and Strehlow, 2000) .
In an unstimulated cell, STATs are monomeric, cytosolic proteins that are in an unphosphorylated state. Cytokine stimulation induces phosphorylation of tyrosine residues on the receptor that serve as docking sites for STATs via their SH2 domains. Once bound to the receptor, all members of the STAT family become tyrosine phosphorylated in response to cytokine stimulation at a conserved C-terminal tyrosine, Y694 for example, in the case of STAT-5. Phosphorylation of this tyrosine appears to be achieved by growth factor receptors as well as by JAK and Src kinases, depending on the nature of the cell type and the ligand/receptor interactions. This form of phosphorylation induces STAT homo-and heterodimerization via the interaction of the SH2 domain of one STAT molecule with the phosphotyrosine residue of another. Once phosphorylated, the dimerized STATs are then able to translocate to the nucleus. In addition to tyrosine phosphorylation, several STATs are regulated by serine phosphorylation at a conserved PSMP motif, which is located in the transactivation domain. C-terminal serine phosphorylation is stimulated by several cytokines and is mediated by serine/threonine kinases including but not limited to extracellular responsive kinase, p38, JNK and protein kinase C-d and positively regulates the transactivation potential of these proteins (reviewed in Khwaja, 2006) . Kovarik et al. (2001) demonstrated that the specificity of signaling by STAT-1 depends on SH2 and C-terminal domains that regulate Ser727 phosphorylation, thereby differentially affecting specific target gene expression. It is known that complete activation of STAT-1 requires phosphorylation at both Y701 and S727. Interestingly, S727 phosphorylation of STAT-1 in IFN-g-treated mouse fibroblasts occurred without a need for p38 mitogen-activated protein kinase (MAPK), extracellular responsive kinase-1 and -2 or JNK, and required both an intact SH2 domain and phosphorylation of Y701. In contrast, ultraviolet-induced STAT-1 phosphorylation on S727 required p38 MAPK, but no SH2 domainphosphotyrosine interactions. Mutation of S727 differentially affected IFN-g target genes, at the level of both basal and induced expression. Furthermore, S727 of STAT-3 is phosphorylated in response to stimuli that differ from those for STAT-1 S727, and transfer of the STAT-3 C terminus to STAT-1 changed the pathway specificity of STAT-1 Ser727 phosphorylation to that of STAT-3. This series of experiments shows that STAT C termini contribute to the specificity of cellular responses by linking individual STATs to different kinase pathways and doing so through an intrinsically different requirement for serine phosphorylation at different target gene promoters. 
Cytokine signaling and signal transducers and activators of transcription activation by Janus kinases and Src family kinases
Because the cytokine receptor-ligand interactions result in the activation of JAKs, which often exist in association with cytokine receptors, and because this activation is obligatory for the activation of STATs, it is widely accepted that STATs are substrates for JAKs. This notion is supported by early studies such as that of Flores-Morales et al. (1998) , which showed in vitro phosphorylation of purified STAT-5 by JAK2. This study also showed STAT-5 in its non-phosphorylated form was able to form a stable complex with activated JAK2, whereas non-activated JAK2 and phosphorylated STAT-5 were unable to participate in complex formation. A second line of evidence, which suggests that JAKs are activators of STATs, stems from the use of dominant-negative mutants. Overexpression of dominant-negative JAK1 and TYK2 mutants can suppress transcriptional activation of a reporter gene downstream from an IFN-a/b-stimulated response element and inhibit STAT-1 and -2 phosphorylation (Krishnan et al., 1997) .
In spite of these and other studies, activated JAKs do not seem to exhibit specificity for a particular STAT, as different receptors activate a common STAT even though they activate distinctively different JAKs (Darnell, 1997; Kohlhuber et al., 1997) . In addition, chimeric receptor molecules that harbor different JAK-binding sites but the same STAT-binding site can activate the same STAT (Kotenko et al., 1996; Kohlhuber et al., 1997) . Thus, the specificity for STAT phosphorylation appears to be determined by the docking sites for STATs that are present in the receptors themselves.
The notion that STATs are activated by kinases other than JAKs was at first supported by indirect evidence. For example, IL-3 stimulation leads to activation of JAK2 and phosphorylation as well as activation of STAT-5a and -5b, and mutational studies have shown that JAK2 is essential for STAT activation (Caldenhoven et al., 1995; Mui et al., 1995a, b; Kouro et al., 1996; Matsuguchi et al., 1997; Smith et al., 1997) . However, a C-terminal mutant of the b c -subunit has been described that can activate JAK2 but is unable to activate STAT-5, indicating that activation of JAK2 alone is not sufficient for STAT-5 activation (Smith et al., 1997) .
A role for Src kinases in STAT activation was first suggested by studies aimed at investigating the molecular mechanisms associated with Src-mediated transformation.
v-Src-transformed NIH3T3 cells constitutively express tyrosine-phosphorylated STAT-3 (Yu et al., 1995; Cao et al., 1996) and in vitro studies have shown that v-Src can bind to and phosphorylate STAT-3 (Cao et al., 1996) . Similarly, v-Src-transformed 32Dcl3 myeloblastic cells constitutively express phosphorylated forms of STAT-1, -3 and -5 in the absence of cytokine (Chaturvedi et al., 1997) . In this model, STAT-3 activation is blocked by a dominant-negative mutant of Src, but not that of JAK-2 (Chaturvedi et al., 1998) . These events mirror the signaling events induced by IL-3 stimulation, whereby the same STATs are activated and endogenous c-Src associates with and mediates the activation of STAT-3.
Taken together, these results suggest that Src family kinases mediate the phosphorylation of STAT-3 mediated by IL-3R interactions and play a critical role in signal transduction pathways associated with myeloid cell proliferation. These results also suggest that activation of STAT-3 following cytokine stimulation of certain hematopoietic cells might follow a very different pathway from that seen with STAT-5. Whereas one or both isoforms of STAT-5 interact directly with JAK2, which in turn mediates their phosphorylation, STAT-3 activation might require its interaction with c-Src, which in turn mediates its phosphorylation (Chaturvedi et al., 1998) . Based on these results, a second model of STAT activation has been proposed, where JAKs may be more crucial to phosphorylation of cytokine/growth factor receptors. Moreover, JAKmediated phosphorylation may create docking sites on the receptors for binding of SH2-containing proteins such as STATs, Src kinases and other signaling intermediates (Reddy et al., 2000) . JAKs or Src kinases, depending on the nature of STAT that is being activated, then induce tyrosine phosphorylation and activation of STAT proteins (Figure 3) .
The notion that different STATs might be phosphorylated by different tyrosine kinases under different conditions is supported by studies with other tyrosine kinases. Examination of the molecular mechanisms associated with v-Abl-mediated transformation shows that B cells transformed by this oncogene exhibit constitutively activated forms of JAK1, JAK3 as well as STAT-1, -3 and -5 (Danial et al., 1995 (Danial et al., , 1998 . Activated JAK1 in these cells was found to be associated with the v-Abl protein. In addition, a dominant-negative mutant of JAK1 was found to inhibit STAT activation mediated by v-Abl, suggesting that the v-Abl protein activates STATs via activation of JAK1. It is also interesting to note that a C-terminal deletion mutant of IL-3bc, termed bc541, was found to be deficient in its ability to activate STAT-5, while still being able to activate JAK2 (Smith et al., 1997) . These observations also imply that while JAK2 activation is a critical step in IL-3/-5/GM-CSF-mediated activation of their cognate receptors, it is by itself not adequate for STAT activation. In sharp contrast, the BCR-ABL oncogene constitutively activates STAT-1 and -5, with very little or no effect on the activation of JAKs (Carlesso et al., 1996; Frank and Varticovski, 1996; Ilaria and Van Etten, 1996; Nieborowska-Skorska et al., 1999) Unlike v-Abl-transformed B cells, overexpression of dominantnegative JAK mutants in these cell lines had no effect on STAT phosphorylation (Ilaria and Van Etten, 1996) . Similarly, Philadelphia chromosome-positive K562 cells express constitutively activated STAT-5 and overexpression of a dominant-negative STAT-5 suppresses their transformed state.
Another line of evidence comes from the early study of Kazansky et al. (1999) , who studied the DNA binding and tyrosine phosphorylation of STAT-5a and -5b following PRL stimulation or Src activation. Their results show that following PRL activation, both STAT5a and -5b were rapidly phosphorylated and translocated to the nucleus. Src activation resulted in the same phenotype. While overexpression of a dominant-negative mutant of JAK2 prevented PRL-induced tyrosine phosphorylation and nuclear translocation of STAT-5a and -5b, expression of dominant-negative JAK2 had no effect on the Src-mediated phosphorylation of STATs. Instead, there was a modest increase in the levels of Srcmediated phosphorylation of STAT-5. These studies again suggest that there exist two independent pathways that mediate STAT activation, one that is dependent on JAKs and the other that is dependent on Src kinases. The context of the cytokine and cell type appears to play a critical role in determining as to which pathway is utilized by the cell.
Targets of signal transducers and activators of transcriptions
The number of STAT responsive genes is vast. However, depending on the specific STAT protein that is expressed and the cell type in which it is expressed, the nature of the target genes that are repressed and/or activated can vary or be remarkably similar. For example, IFN-g, via STAT1, induces an 'interferon signature' that is common among cell types and includes genes such as Irg47, Ifi202 and 204, Irf1 and ISG15. STAT1 appears to have tumor-suppressive properties and, as such, it has been shown to positively regulate the expression of caspases and negatively regulate that of antiapoptotic Bcl-2 family genes (reviewed in Alvarez and Frank, 2004; Haura et al., 2005) . It has also been shown to bind to the STAT-responsive element located within the p21 (CDKN1A) known to negatively regulate the kinase activity of CDK2, an important enzyme that mediates cell-cycle progression (Bromberg et al., 1996; Chin et al., 1996) .
However, other STATs, such as STAT-3, -5 and -6, regulate genes in a more cell-type restrictive manner, whereby the set of genes that is induced in response to a given cytokine differs from one cell type to the next (reviewed in Murray, 2007) . STAT-3 and -5 have both been shown to play key roles in cellular transformation and hence it is not surprising that these proteins regulate the expression of genes that control processes such as proliferation, apoptosis and angiogenesis. Depending on the cell type and cytokine, STAT3 regulates the expression of genes such as the Bcl-2 family, survivin and Fas and suppresses apoptosis. In a myeloma model, IL-6-mediated activation of STAT-3 results in the upregulation of Bcl-x L , while similar activation of STAT-3 in T lymphocytes results in the transcriptional upregulation of Mcl-1, another member of the Bcl-2 family. STAT-3 has also been shown to bind to the promoter of the Survivin gene, a member of the inhibitors of apoptosis (IAP) family, and upregulate its expression (Gritsko et al., 2006) . In addition to the positive regulation of prosurvival genes, STAT-3 also appears to regulate genes important for cell-cycle regulation, which include MYC and cyclin D1. It also promotes angiogenesis and invasion by directly binding to the promoters of the vascular endothelial growth factor and matrix metalloproteinase-2 genes, respectively. In addition to upregulating the growth-promoting genes, STAT-3 has also been found to negatively regulate death-inducing genes such as tumor necrosis factor (Niu et al., 2001) . STAT-5 behaves similarly in that it too regulates the expression of Bcl-2 family members (such as Bcl-x L ) and proliferation-associated genes such as c-myc, cyclin D2 and pim-1 (reviewed in Haura et al., 2005) . However, it is important to note that regulation of target gene expression by both of these STATs may not overlap with respect to tissue type and stimulus. Table 2 provides a partial list of some STAT-1, -3 and -5 target genes.
Other pathways activated by cytokines IL-3 as well as a number of other cytokines activate multiple signal-transduction pathways, including the Ras and PI3K pathways. Upon IL-3 stimulation, the adaptor molecule Shc is rapidly phosphorylated and associates with the phosphorylated b c -subunit of the IL-3R. IL-3 stimulation also results in tyrosine phosphorylation of the inositol phosphatase (SHIP), which forms a complex with Shc, Grb2 and Sos. Upon recruitment, Shc binds to the phosphorylated Y577 of the b c -subunit and subsequently interacts with the adaptor protein Grb2, which in turn associates with mSos, a nucleotide exchange factor for Ras. This is followed by the activation of Ras and c-Raf as well as the subsequent downstream activation of the MAPKs, extracellular responsive kinase-1, -2 and p38. Activation of this cascade culminates in the increased expression of transcription factors c-fos and c-jun (reviewed in Reddy et al., 2000) and the activation of STATs. STAT proteins serve as substrates for MAPKs whereby the conserved C-terminal serine residue in their transactivation domains is phosphorylated by MAPKs Zhang et al., 1995; Jain et al., 1998; David et al., 1995a, b) and protein kinase C (Jain et al., 1999; Gartsbein et al., 2006) , thus enhancing their transcriptional activity.
IL-3/IL-5 and GM-CSF also induce a rapid activation of the lipid kinase PI3K. Interestingly, the same region of the b c -subunit that is responsible for the activation of the Ras pathway seems to be involved in signaling via PI3K. PI3K associates with the b c -subunit and this interaction may be influenced by the adaptor protein p80. The p80 adaptor protein acts as a scaffold that interacts with the b c chain, the p85 subunit of PI3K and Src kinases in IL-3-stimulated cells. Downstream proteins recruited by the PI3K pathways upon IL-3 stimulation include AKT. PI3K-dependent activation of protein kinase B/AKT in response to IL-3 stimulation has been observed in multiple cells lines and these studies suggest a role for this pathway in the transmission of cell-survival signals in response to IL-3 (reviewed in Reddy et al., 2000; Figure 4 ).
Negative regulation of Janus kinases-signal transducers and activators of transcription signaling
Negative regulation by protein tyrosine phosphatases Protein tyrosine phosphatases (PTPs) regulate the activities of kinases and other proteins by dephosphorylating tyrosine residues (reviewed in Pallen et al., 1992) . Three types of PTPs have been shown to negatively regulate JAK-STAT pathways. The first phosphatases that demonstrated a regulatory role in this pathway are the SH2-containing phosphatases (SHPs), SHP1 (perviously termed PTP1C) and SHP2 (previously termed PTP1D). Each is characterized by the presence of two SH2 domains in addition to a C-terminal phosphatase catalytic domain. SHP1 is primarily expressed in hematopoietic cells, while the expression pattern of SHP2 is more ubiquitous. These proteins, which act via association of their SH2 domains with phosphotyrosine residues, have been shown to dephosphorylate both activated cytokine receptors and JAKs that have been recruited to receptor complexes. Dephosphorylation of receptors also prevents their association with STATs and thus this represents an indirect method of STAT inhibition (reviewed in Valentino and Pierre, 2006) . Loss of phosphotyrosine residues to which SHP1 binds on the Epo, IL-3, -5 and GM-CSF receptors results in sustained JAK activation (Yi et al., 1993; Klingmuller et al., 1995) , although SHP2 has been reported to function as both a positive and negative regulator of cytokine receptor signaling (reviewed in Neel et al., 2003) . SHPs have also been shown to bind JAKs directly and mediate their dephosphorylation (David et al., 1995a, b; Jiao et al., 1996; Haque et al., 1998; Migone et al., 1998) . Detailed analysis has revealed that SHP2 is tyrosine phosphorylated by JAK1 and JAK2 but not by JAK3, on Y304 and Y327 via direct association. The SHP-2 and JAK association does not require the SH2 domain of SHP2 or the JH2 domain of JAKs, but does require the N-terminal region of JAK proteins and regions encompassing amino-acid residues 232-272 on the SHP2 protein. Interestingly, SHP-2 phosphatase activity seems to be non-essential for JAK-SHP2 interactions, as mutations that render SHP2 inactive do not abolish the interaction between SHP2 and JAKs.
The second phosphatase that negatively regulates JAK-STAT signaling is the transmembrane PTPase CD45, which is highly expressed in all hematopoietic lineages at all stages of development and is a key regulator of antigen receptor signaling in T and B cells. Although Src family kinases were identified as primary molecular targets for CD45, targeted disruption of the CD45 gene leads to enhanced cytokine and IFN receptor-mediated activation of JAKs and STAT proteins. In vitro, CD45 directly dephosphorylates and binds to JAKs and negatively regulates IL-3-mediated cellular proliferation, Epo-dependent hematopoiesis, IFN-mediated antiviral responses (Irie-Sasaki et al., 2001) and IL-4/anti-CD40-induced switch recombination (Yamada et al., 2002) .
Phosphotyrosine phosphatase 1B and T-cell protein tyrosine phosphatase (TC-PTP) share sequence similarities in their catalytic domains and comprise the third group of phosphatases that regulate JAK-STAT signaling. Phosphotyrosine phosphatase 1B is localized to the endoplasmic reticulum and is expressed in several tissues. TC-PTP, on the other hand, is primarily expressed in hematopoietic cell types and exists in two forms due to alternative splicing. p45 (TC45 or TC-PTPa) is localized to the nucleus, whereas the longer p48 isoform (TC48 or TC-PTP1b) is cytoplasmic. Phosphotyrosine phosphatase 1B and TC-PTP proteins recognize tyrosine residues in the JAK activation loop although the specificity for surrounding residues differs. Hence, JAK2 and TYK2 are physiological substrates of phosphotyrosine phosphatase 1B (Myers et al., 2001) , whereas JAK1 and JAK3 are substrates for TC-PTP (Simoncic et al., 2002) . TC-PTPa has also been shown to inactivate STAT-1, STAT-3 (ten Hoeve et al., 2002) and STAT-6 (Lu et al., 2007) .
Negative regulation of Janus kinases by suppressors of cytokine signaling family proteins The CIS (cytokine-induced SH2 containing proteins)/ SOCS (suppressors of cytokine signaling)/STAT-induced STAT inhibitor/JAK-binding protein family of proteins possess SH2 domains that allow proteinprotein interactions with members of the cytokine receptor family and other signaling components.
Although this family has members with many diverse names, they are commonly referred to as SOCS proteins. The SOCS proteins, which were cloned simultaneously by several independent groups, are small proteins that possess central SH2 domains and conserved C-terminal SOCS/CIS boxes (Endo et al., 1997; Naka et al., 1997; Starr et al., 1997) . CIS, the first identified member of the family, was cloned as an early response gene for IL-2, IL-3 and Epo and was found to be associated with these receptors (Yoshimura et al., 1995; Matsumoto et al., 1997; Verdier et al., 1998) . Moreover, overexpression of CIS led to a suppression of signaling in response to IL-3 and Epo. SOCS1 (also known as SSI1 or JAK-binding protein) was later identified as a potent inhibitor of JAKs (Endo et al., 1997; Naka et al., 1997; Starr et al., 1997) . Interestingly, SOCS genes for CIS, SOCS1, -2 and -3 are rapidly upregulated at the transcriptional level following cytokine stimulation (Starr et al., 1997) , and the presence of g-activated sequence elements in their promoters suggests that their expression is regulated as part of a negative-feedback loop (reviewed in Valentino and Pierre, 2006) .
To date, there are eight members of the SOCS family, CIS and SOCS1-7. (SOCS proteins, with the exception of SOCS4, have more than one name) (reviewed in Krebs and Hilton, 2001 ).Taken together, there are three general methods by which these proteins regulate JAK-STAT activity. The first is by competing with JAKs and STATs for binding to receptors. As mentioned above, CIS is associated with several cytokine receptors, including the Epo receptor. In this case, CIS binds to the STAT-5 binding site of the receptor (at Y401), prevents STAT-5 binding and inhibits STAT-5-mediated signaling (Yoshimura et al., 1995) . SOCS5 also associates with the IL-4R and inhibits JAK1-mediated signaling by a similar mechanism (Seki et al., 2002) .
The second method by which SOCS proteins negatively regulate JAK-STAT signaling is by binding to JAKs directly. SOCS1, via its SH2 domain, binds to Y1007 in the activation loop of JAK2. Originally identified as negative regulators of IL-6 signaling (Starr et al., 1997) , subsequent studies have revealed that some SOCS proteins, such as SOCS1 and SOCS3, possess a kinase inhibitory region that is believed to compete with substrates of JAKs (reviewed in Khwaja, 2006) and peptides that correspond to this region can function as SOCS1 antagonists (Waiboci et al., 2007) .
The third way in which SOCS proteins inhibit JAK-STAT pathways is by promoting ubiquitination and subsequent proteasome-mediated degradation of JAKs. SOCS proteins function as part of an E3 ubiquitin ligase complex and in vitro, SOCS1 has been shown to target JAK2 for ubiquitination (Ungureanu et al., 2002) .
Negative regulation of signal transducers and activators of transcriptions by protein inhibitor of activated STAT proteins Protein inhibitor of activated STAT (PIAS) family proteins were originally described as negative regulators of STAT signaling but have since been shown to exhibit activity toward a variety of transcription factors. These proteins contain an N-terminal LXXLL co-regulator motif, a zinc-finger domain and a C-terminal acidic domain. There are five PIAS proteins (PIAS1, PIASx, PIAS3a and -b, PIASy), and all bind to activated STAT dimers and inhibit STAT-mediated transcription by distinct mechanisms. PIAS1 and PIAS3 associate with STAT-1 and -3, respectively, and directly inhibit DNA binding. PIASx interacts with STAT-4, although it and PIASy act by a different mechanism whereby they regulate the recruitment of transcriptional repressors such as histone deacetylases (HDAC's) to the promoters of their target genes (reviewed in Rakesh and Agrawal, 2005; Khwaja, 2006) . Recent studies have demonstrated that some PIAS family members possess small ubiquitin-like modifier E3-ligase activity and mediate the sumoylation of STATs (Ungureanu et al., 2003 (Ungureanu et al., , 2005 . This form of protein modification is similar to ubiquitination but does not promote degradation. Rather, it has been shown to alter subcellular localization and protein-protein interactions, which alter protein activity and stability.
Other forms of negative regulation
Recently, an E3 ubiquitin ligase was isolated that targets STAT proteins for proteasome-mediated degradation. This protein, termed SLIM (Tanaka et al., 2005) , mediates the degradation of STAT-1 and -4 and enhances their dephosphorylation. In addition to specific protein families that bind to and regulate JAKs and STATs directly, there are other mechanisms by which cytokine receptor signaling is inhibited. Cells often express soluble forms of receptors that compete with their membrane-bound counterparts and compete for ligand binding, and membrane-bound receptors can also undergo endocytosis (reviewed in Kisseleva et al., 2002) .
Conclusion and future directions
It is becoming increasingly evident that the interaction of cytokines with their receptors leads to the activation of multiple signal-transduction pathways, which can be extraordinarily similar, even for different cytokines. In spite of what appears to be an 'overlap' in pathways, each cytokine elicits different biochemical and biological responses, even those cytokines that share the same signal-transducing receptor unit. JAKs and STATs are key players in this process, and a detailed understanding of how they transduce signals will go a long way toward enabling us to develop targeted therapies that are specific for these protein families. For example, it has been known for about a decade that certain STATs are constitutively activated by BCR-ABL, the oncoprotein expressed in Philadelphia chromosome-positive chronic myelogenous leukemias. A comparison of the similarities between this form of STAT activation versus that induced by cytokines has shed light on how STAT proteins function. Similarly, the JAK2 V617F mutation that is present in other myeloproliferative disorders has revealed the importance of the JAK pseudokinase domain and the requirement of cytokine receptors in JAK activation. Future studies in these rapidly evolving areas will undoubtedly continue to reveal more information about JAKs and STATs and how tumor cells exploit them to induce disease.
